Yeah, would love to hear an update as to progress on their OSA program/plans. Have preclinicals with new formulations been going on or successful to set up a phase 3 human trial? There is 0 valuation for the OSA program shown in the current market cap of RSPI.
IMO however, the pain/epilepsy candidate is the real big time asset that can potentially bring significant BP dealings.